Clinical Edge Journal Scan

Independent risk factors-based referral tool may help identify PsA in psoriasis


 

Key clinical point: A referral tool based on five independent risk factors for concomitant psoriatic arthritis (PsA) among patients with psoriasis may help dermatologists to identify patients with psoriasis who could benefit from a rheumatologist referral.

Major finding: The predictive variables for concomitant PsA among patients with psoriasis that were included in the referral tool were treatment history with conventional systemics ( P = .04) and biologics/small molecule inhibitors ( P = .01), patient-reported history of joint pain without trauma ( P = .02), swollen joints ( P < .001), and sausage-like swollen digits ( P = .01). The referral tool had an area under curve of 0.82.

Study details: This study analyzed the data of 303 patients with psoriasis from the prospective observational DAPPER study who had visited the dermatology outpatient clinic.

Disclosures: This study was funded by a PhD grant from Radboud University Medical Center/Sint Maartenskliniek, Netherlands, and local structural research funding of the Sint Maartenskliniek. Several authors reported financial and non-financial ties with various sources.

Source: van Hal TW et al. Development of a new referral tool to identify psoriasis patients with concomitant psoriatic arthritis: Results of the prospective DAPPER cohort. Acta Derm Venereol. 2023 (Apr 27). Doi: 10.2340/actadv.v103.5269

Recommended Reading

Secukinumab improves treatment outcomes and inhibits structural damage in PsA
MDedge Rheumatology
Enthesitis resolution similar with secukinumab and adalimumab in PsA
MDedge Rheumatology
Sonographic enthesitis associated with sonographic synovitis and tenosynovitis in PsA
MDedge Rheumatology
Upadacitinib safe and effective in PsA patients with axial involvement
MDedge Rheumatology
Entheseal fibrocartilage abnormalities: A potential imaging biomarker of PsA
MDedge Rheumatology
Concomitant methotrexate has no effect on ustekinumab immunogenicity in PsA
MDedge Rheumatology
Concomitant methotrexate has no effect on ustekinumab immunogenicity in PsA
MDedge Rheumatology
Pretreatment systemic inflammatory markers may guide therapeutic approach in PsA
MDedge Rheumatology
Interleukin-17A inhibitor secukinumab safe and effective in oligoarticular PsA
MDedge Rheumatology
Low extent and incidence of radiographic spinal damage in PsA vs spondyloarthritis
MDedge Rheumatology